Due to excellent turnover, JB Chemical & Pharmaceutical boosted its total earnings by 32.41 percent to Rs 97.88 crore again for the latest quarter on September 30, 2021.
In a report to the BSE, JB Chemicals & Pharmaceuticals found that the company made a profit post taxation of 73.92 crores in the previous fiscal’s comparable timescale.
For the quarter under review, the company’s consolidated revenue from operations was Rs 593.01 crore. It was Rs 443.56 crore a year earlier, according to the company.
Despite pandemic-related challenges and supply chain uncertainties, JB Chemicals & Pharmaceuticals CEO and Wholetime Director Nikhil Chopra noted, “Our outstanding operational performance has contributed to market-beating growth in India and steady performance in overseas operations.”
Several measures, including a re-aligned Go-To-Market approach, diversification into complementary medicines, and new releases, have helped the company maintain its growth momentum in India, resulting in market share increases and improved rankings, he noted.
“While worldwide business faces external market issues, our main markets, such as South Africa and the United States, have performed well, and Russia is showing signs of gradual revival,” Chopra explained.
JB Chemicals & Pharmaceuticals’ stock ended the day on the BSE at Rs 1,657.40, down 5.07 percent from the previous closing.
This is it!! Feel free to share your feedback with us in the comment section below.